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Background: The pathogenesis of heart failure after myocardial infarction is associated with the 
pathogenesis of cardiac remodeling. Galectin-3 (Gal-3) has a role in the pathophysiology of cardiac 
remodeling after acute myocardial infarction. N-Acetylcysteine (NAC) can prevent inflammation, 
remodeling and left ventricular dysfunction, interstitial fibrosis, and improve survival. The purpose 
of this study was to examine effect of oral N-Acetylcystein on Galectin-3 in acute myocardial 
infarction patients. 
Subjects and Method : This was an experimental study with pre and post, single blind, and 
randomization methods. The study was conducted at Dr.Moewardi General Hospital Surakarta, 
Central Java, from June to August 2018. A sample of 29 acute myocardial infarction patients with 
ST segment elevation who received fibrinolytic therapy was selected for this study. 14 patients as a 
control group received standard therapy and 15 patients as intervention group received oral NAC 
supplementary therapy 600 mg three times daily for three days. The dependent variable was Gal-3 
levels. The independent variable was NAC supplementary therapy.The data were analyzed by Mann 
Whitney test. 
Results : Gal-3 levels in intervention group (mean= 8.95; SD=1.76) were lowered than the control 
group (mean= 11.42; SD= 3.76) and it was statistically significant (p= 0.026).  
Conclusion : Supplementary therapy of NAC 600 mg orally 3 times a day for 3 days can reduce 
levels of Gal-3 in patients with acute myocardial infarction who receive fibrinolytic therapy. 
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BACKGROUND 
Coronary heart disease is the leading cause 
of death worldwide (Hartley et al., 2016). 
Death from cardiovascular disease in Indo-
nesia is increasing every year and cardio-
vascular disease is the most common cause 
of death (Dharma et al., 2012). More than 
three million people are estimated to suffer 
from IMA EST and more than four million 
people suffer from non-EST IMA. Previous-
ly IMA was more common in developed 
countries, but currently the incidence of 
IMA is increasing in developing countries 
(White and Chew, 2008). Data obtained 
from Jakarta Acute Coronary Syndrome 
(JAC) Registry from 2008-2009 were 
obtained in 2013 patients with acute coro-
nary syndrome, of which 654 patients 
suffered IMA EST and 622 patients 
suffered non-EST IMA treated at the 
Harapan Kita National Heart Center 
(Dharma et al. , 2012). 
In a study in patients with IMA, there 
was a decrease in 5-year mortality rates 
(from 41.1% in the 1970s to 17.3% in the 
1990s) associated with a significant incre-
Indonesian Journal of Medicine (2019), 4(1): 1-8 
https://doi.org/10.26911/theijmed.2019.04.01.01 
2   e-ISSN: 2549-0265 
ase in the incidence of heart failure in 5 
years (from 27.6 % in the 1970s to 31.9% in 
the 1990s) (Velagaleti et al., 2008). The 
pathogenesis of heart failure after myocar-
dial infarction is associated with the patho-
genesis of cardiac remodeling, a constella-
tion of geometric, morphological, molecular 
and functional changes involving or not 
myocardial infarction, causing space dilate-
tion and ventricular dysfunction, and asso-
ciated with poor outcome. The severity of 
post-infarction myocardial remodeling 
depends, not only on infarct size, but also 
on the qualitative characteristics of the 
reparative response (Pfeffer and Braun-
wald, 1990). 
N-Acetylcysteine (NAC) can prevent 
inflammation, left ventricular remodeling 
and dysfunction, interstitial fibrosis, and 
improve survival in animal studies (Waard 
et al., 2009). In patients with fibrinolytic 
IMA EST, administration of NAC can 
reduce the levels of matrix metallopro-
teinase (MMP) -9 and 2 which play a role in 
post-infarct heart remodeling while re-
ducing major adverse cardiac events 
(MACE) in meaningful one-year follow-up 
(Talasaz et al., 2014). Reduction in infarc-
tion size also occurred significantly with the 
administration of NAC in IMA EST patients 
who performed percutaneous coronary 
intervention (IKP) primers (Pasupathy et 
al., 2017). 
Remodeling after myocardial infarc-
tion is caused by acute loss of myocardium, 
which causes structural and biomechanical 
changes in an effort to maintain cardiac 
function. Formation of fibrous tissue is 
important in this case, including in the 
initial phase and further conditions after 
the IMA. Galectin-3 (Gal-3), a lectin that 
binds to β-galactoside, has a major role in 
the development of heart fibrosis under 
conditions of excessive pressure (pressure 
overload), neuro-endocrine activation, and 
hypertension, but its role in remodeling 
after IMA has not gotten enough attention. 
However, in various studies in rats, it 
showed Gal-3 expression in the myocard-
ium after increased myocardial infarction, 
both at the level of mRNA and protein, 
during the initial phase in the infarct and 
surrounding areas, and also in the 
advanced phase which contributed to tissue 
repair and fibrosis (Meijer et al., 2015; 
Sharma et al., 2016). 
Van der Velde et al. (2016), 247 IMA 
EST patients who underwent primary IKP, 
Gal-3, as biomarkers of fibrosis, who were 
taken after IMA could predict left ventri-
cular ejection fraction and infarct area after 
4 months. Therefore from this study it is 
concluded that Gal-3 has a role in the 
pathophysiology of cardiac remodeling 
after IMA. Genetic disruption and pharma-
cological inhibition of Gal-3 can reduce 
heart fibrosis, left ventricular dysfunction 
and the development of heart failure, giving 
rise to the impression that administration 
of drugs related to Gal-3 inhibition can be 
potential therapeutic candidates to prevent 
or improve the incidence of heart failure 
with extensive fibrosis (Yu, 2012). To the 
knowledge of the researchers, until now 
there has been no research on the effect of 
additional oral N-Acetylcystein therapy on 
Gal-3 levels in patients with IMA receiving 
fibrinolytic therapy. 
 
SUBJECTS AND METHOD 
1. Study Design 
This was a randomized controlled trial 
carried out at Dr. Moewardi Hospital, Sura-
karta, Central Java, from June to August 
2018.  
2. Study Subjects 
A sample of 29 acute myocardial infarction 
patients with ST segment elevation who 
received fibrinolytic therapy was selected 
for this study by concecutive sampling. 
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Samples were taken consecutively in pati-
ents with IMA EST who received fibrino-
lytic therapy who were treated at ICVCU 
and were willing to take blood for this 
study. 
Inclusion criteria, namely patients 
with IMT EST with symptom onset of less 
than 12 hours and fibrinolytic action, pati-
ents aged 18-75 years, and no absolute 
contraindications to the action of fibri-
nolysis. As for exclusion criteria, namely 
patients with a history of previous SKA or 
chronic heart failure, patients with valvular 
heart disease, patients with chronic renal 
failure, patients with hepatic cirrhosis, 
patients with chronic inflammatory disease 
or malignancies, patients with acute infect-
ion or sepsis, and patients with acute 
stroke. 
3. Study Variables 
Acute myocardial infarction with ST seg-
ment elevation was defined by clinical syn-
drome with typical symptoms of chest pain 
as a symptom of myocardial ischemia asso-
ciated with ECG images in the form of ST 
segment elevation calculated from point J 
in at least 2 adjacent leads ≥2 mm (0.2 mV) 
in men or ≥1.5 mm (0.15 mV) in women in 
leads V2-V3 and or ≥1 mm (0.1 mV) in 
other leads in the chest or limb leads and 
release of biomarkers of myocardial necro-
sis (Ibanez et al., 2017).  
Fibrinolytic was indicated in IMA 
patients with ST segment elevation and 
patients coming to hospital within 12 hours 
after symptoms are first felt. In this study 
fibrinolytics used a 1.5 million unit Strepto-
kinase preparation diluted in 100 cc NaCl 
and inserted intravenously for 30-60 
minutes (Ibanez et al., 2013).  
N-Acetylcysteine used was a 600 mg 
effervescent tablet (Fuimucil®, Zambon 
Switzerlan Ltd) with treatment given 3x600 
mg for 3 days. Gal-3 levels were measured 
using Human Galectin-3 Quantikine ELISA 
(R & D System, USA). 
4. Data analysis 
Data presented in the form of a mean and 
standard deviation were then analyzed 
between treatment and control groups 
before and after treatment. The data were 
analyzed by Mann Whitney test.  
5. Research Ethics 
Research ethics including informed con-
sent, confidentiality, and ethical clearance 
was obtained from Dr. Moewardi hospital, 
Surakarta, Central Java. 
 
RESULTS 
A total of 29 patients were included in this 
study: 14 control group patients who 
received standard therapy and 15 group 
patients who received oral NAC supplemen-
tary therapy 600 mg three times a day for 
three days. The results of testing the homo-
geneity of the subject's basic characteristic 
variables, both qualitative and quantitative, 
found that all basic characteristic variables 
were homogeneous because the mean 
differences in the characteristic variables in 
the two groups namely the NAC group and 
the control group were not significant at the 
5% significance level 0.05). 
The results of different tests 2 the 
mean NAC group and control group for the 
Gal-3 variable in the condition after admi-
nistration of therapy showed significant test 
results (p = 0.026). Thus the variable levels 
of Gal-3 for NAC and the control group in 
conditions after administration of therapy 
differed significantly or not the same. This 
can be interpreted that after getting stan-
dard therapy plus NAC in the NAC group 
and standard therapy alone in the control 
group, there was a significant difference in 
the variable Gal-3 level, because the NAC 
group changed while the control group 
tended to remain.  
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Table 1. Univariate analysis 
Independent Variable 
Control Group NAC Group Chi Square Test 
n % n % OR p 
Geder 
a. Male 12 85.7 14 93.3 
0.453 0.501 
b. Female 2 14.3 1 6.7 
Type of Location of IMA EST 
a. Anterior 8 57.1 10 66.7 
0.279 0.597 
b. Non-Anterior 6 42.9 5 33.3 
Killip class 
a. 1 10 71.4 11 73.3 
0.013 0.909 
b. 2-4 4 28.6 4 26.7 
Hypertension Status 
a. Yes 9 64.3 10 65.5 
0.018 0.893 
b. No 5 35.7 5 34.5 
Smoking Status  
a. Yes 9 64.3 11 73.3 
0.277 0.599 
b. No 5 35.7 4 26.7 
Status Diabetes mellitus 
a. Yes 1 7.1 4 26.7 
3.137 0.077 
b. No 13 92.9 11 73.3 
Status of Fibrinolytic Success 
a. Succeed 3 21.4 2 13.3 
0.333 0.564 
b. Failed 11 78.6 13 86.7 
 
Table 2. Sample Characteristics  
Variable 
Control Group NAC Group 2Average Difference Test  
Mean SD Mean SD Statistical Value p 
Age 58.21 8.37 56.40 10.27 t = 0.519 0.609 
Onset 4.96 2.67 4.93 2.68 t = 0.031 0.975 
SBP 132.36 28.41 137.73 24.88 t = -0.543 0.592 
DBP 81.07 19.38 83.73 17.05 t = -0.393 0.697 
HR 77.71 12.33 74.80 20.20 t = 0.465 0.646 
TIMI Score 4.64 2.34 3.53 1.30 Z = -1.072 0.310 
Hb 13.59 1.88 13.63 1.72 t = -0.071 0.944 
HT 41.43 5.67 41.27 4.37 t = 0.087 0.932 
Leukocytes 10.90 3.73 11.73 4.11 t = -0.571 0.573 
Thrombocytes 247.04 87.78 265.17 62.51 t = -0.644 0.525 
Erythrocytes 4.78 0.62 4.73 0.57 t = 0.218 0.829 
eGFR 73.87 30.30 63.92 25.61 t = 0.957 0.347 
Hs-Trop I 1907.56 1839.14 2107.65 2815.91 Z = -0.393 0.715 
Blood sugar 136.71 32.40 156.47 65.69 t = -1.015 0.319 
LDL 141.29 85.08 130.20 30.28 Z = -0.284 0.780 
LVEF 44.21 8.22 44.60 11.61 t = -0.103 0.919 
SBP= systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, TIMI = Thrombolysis in 
Myocardial Infarction, Hb = hemoglobin, HT = hematocrit, eGFR = estimated glomerular filtration rate, Hs-
Trop I = high sensitive troponin I, LDL= low-density lipoprotein, LVEF= left ventricle ejection fraction 
 
The results of different test 2 mean of 
the variable Gal-3 levels before and after 
therapy in the NAC group produced a 
significant difference (p = 0.001). However, 
the mean difference testing of the Gal-3 
level variables before and after adminis-
tration of therapy in the control group 
produced a non-significant difference (p = 
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0.344). This means that in the NAC group, 
giving standard therapy plus NAC can 
significantly reduce the Gal-3 level variable, 
but in the control group it cannot signify-
cantly reduce the Gal-3 variable. 
Variable changes in Gal-3 levels in the 
NAC group and the control group both have 
data that are normally distributed, so 
different testing 2 mean changes in Gal-3 
levels in the NAC group and the control 
group can use different test 2 mean t test 
for independent samples. The results of the 
calculation of the difference test 2 mean 
with the t test for the independent sample 
between the variable changes in Gal-3 
levels in the NAC group and the control 
group showed that the variable changes in 
Gal-3 levels differed significantly (p= 
0.006). This condition shows that giving 
standard therapy plus NAC in the NAC 
group can actually reduce Gal-3 levels 
significantly.
Table 3. Comparison of Gal-3 levels on NAC and control groups before and after 
treatment 
Variable 
Control Group NAC Group 2 Average Difference Test 
Mean SD Mean SD Statistical Value p 
Before 12.91 4.02 15.99 4.77 t = -1.88 0.072 
After 11.42 3.76 8.95 1.76 Z = -2.23 0.026 
 
Table 4. Comparison of Gal-3 levels before and after therapy NAC and control 
groups 
Variable 
Before After Test t of 2 average difference 
Mean SD Mean SD Statistical Value p 
Control Group 12.81 4.02 11.42 3.76 t = 0.98 0.344 
NAC Group 15.99 4.77 8.95 1.76 t = 6.31 0.001 
 
Table 5. Comparison of changes in (delta) Gal-3 levels in the NAC and control 
groups 
Variable 
Control Group NAC Group 2 Average Difference Test 
Mean SD Mean SD Statistical Value p 
Changes in 
Gal-3 levels 
-1.50 5.70 -7.04 4.33 t = 2.97 0.006 
 
DISCUSSION 
Remodeling after myocardial infarction is 
caused by acute loss of myocardium, which 
causes structural and biomechanical 
changes in an effort to maintain cardiac 
function. Formation of fibrous tissue is 
important in this regard, including in the 
initial phase and further conditions after 
IMA (Meijer et al., 2015; Sharma et al., 
2016). 
Galectin-3 is secreted by macrophages 
which are activated and modulate several 
physiological and pathological processes, 
including inflammation and fibrosis. 
Galectin-3 directly induces fibroblasts to 
proliferate and deposit type I collagen in 
the extracellular matrix (Yang et al, 2008; 
Sharma et al, 2016). In the study by van der 
Velde et al. (2016) with 247 patients with 
IMA EST who underwent primary IKP, Gal-
3, as a biomarker of fibrosis, taken after 
IMA can predict left ventricular ejection 
fraction and infarct area after 4 months. 
Another study by Tano et al (2017) involved 
103 patients with Anterior ESA who had 
occlusion in the left anterior descending 
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artery (LAD) who underwent primary IKP 
then followed for 6 months, remodeling 
occurred in patients with higher Gal-3 at 
the time baseline, 1 month and 6 months. 
The findings of this study showed that 
there were significant differences in Gal-3 
levels between the control group and the 
treatment group after administration of 
NAC 600 mg orally 3 times a day for 3 days, 
there were also significant differences in 
Gal-3 levels in the treatment group before 
and after treatment where this significant 
difference was not found in the control 
group. In addition to that, there was a sig-
nificant decrease (delta Gal-3) between the 
control and treatment groups. Therefore, 
the administration of NAC in this study can 
significantly reduce Gal-3 levels in IMA 
patients receiving fibrinolytic therapy. The 
results of this study are in line with the 
research conducted by Talasaz et al. in 2014 
aimed at evaluating the effect of NAC on 
cardiac remodeling by using MMP-9 and 
MMP-2 levels in 98 IMA patients. In the 
group of patients who received oral NAC 
supplementary therapy, MMP-9 and MMP-
2 levels were significantly lower than the 
placebo group (p= 0.014 and p = 0.045, 
respectively). In the previous year, Talasaz 
et al. (2013) conducted a study to deter-
mine the effect of NAC on pro-fibrotic cyto-
kines, TGF-β, and inflammation, TNF-α, in 
IMA patients. In this study it was 
concluded that administration of NAC can 
prevent TGF-β increases compared to those 
not given and TGF-β has a strong associa-
tion with left ventricular ejection fraction, 
therefore its antagonism may be important 
in preventing remodeling. 
Decreasing Gal-3 levels through NAC 
administration can be explained by an 
indirect inhibiting mechanism through its 
role as an antioxidant and anti-inflamma-
tory. Production of ROS due to myocardial 
ischemia activates inflammatory signals in 
myocardial infarcts. Reactive oxygen spe-
cies increases leukocyte infiltration into 
existing infarcts in the healing process by 
activating all steps of inflammatory cell 
recruitment (Fan et al., 2001; Christia and 
Frangogiannis, 2013). N-Acetylcysteine is a 
ROS scavenger as a direct antioxidant, but 
its main role as a therapeutic antioxidant 
comes from its role as a precursor of cys-
teine in the synthesis of GSH. Under con-
ditions of oxidative stress, the amount of 
GSH is reduced and this can be returned by 
NAC supplementation (Atkuri et al., 2007). 
Induction of pro-inflammatory transcrip-
tion factors activator protein-1 (AP-1) and 
nuclear factor-κB (NF-κB) is inhibited by 
NAC. These transcription factors are 
induced in response to oxidative stress thus 
supporting the argument that the anti-
inflammatory properties of NAC are due to 
its mechanism of action as an antioxidant 
(Pinkus et al., 1996; Radomska and 
Skopiñski, 2012). 
Transforming growth factor-β is an 
important mediator in the remodeling 
process (Talasaz et al., 2011). Differentia-
tion and activation of fibroblasts into myo-
fibroblast by inflammatory cytokines, such 
as TGF-β, preceded by the entry of cells 
such as macrophages is the first step in the 
process of fibrogenesis. Galectin-3 plays a 
role in this process where macrophages and 
TGF-β induce activation of myofibroblast 
through Gal-3, but recruitment of macro-
phages and expression of TGF-β does not 
depend on Gal-3 (Yu, 2012). 
Ischemia that occurs after IMA will 
trigger an increase in levels of pro-fibrotic 
cytokines, TGF-β, which induce fibrotic 
deposition in cardiomyocytes. Transform-
ing growth factor-β plays a significant role 
in the pathogenesis of the remodeling pro-
cess, because inhibitory activity on TGF-β 
in the proliferative phase of remodeling can 
prevent left ventricular hypertrophy and 
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reduce the expansion of fibrosis in seg-
ments of the myocardium that do not expe-
rience infarction, and improve geometry 
left ventricle. N-Acetylcysteine can convert 
this cytokine into its inactive form and 
inhibit the binding of these cytokines to its 
receptors. On the other hand, fibronectin, a 
glycoprotein involved in tissue remodeling, 
can be released in response to various cyto-
kines that include TGF-β as the strongest 
stimulator. Thus, through inhibition of 
fibronectin production induced by TGF-β, 
NAC can be effective in blocking tissue 
remodeling (Sugiura et al., 2009). 
Based on the results of this study, it 
can conclude that NAC 600 mg adminis-
tration as an additional therapy orally 3 
times a day for 3 days can influence by 
decreasing Gal-3 levels in IMA patients 
receiving fibrinolytic therapy compared to 
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